ArriVent: Phase 3 FURVENT misses primary PFS endpoint by BICR; signals on secondary endpoints
ArriVent's Phase 3 FURVENT trial of firmonertinib missed the primary PFS endpoint by BICR (p=0.0654). The 240mg arm showed median PFS of 11.0 months vs. 9.5 months for control. Investigator-assessed PFS favored 240mg (11.1 vs. 7.1 months). Confirmed ORR by BICR was 60% for 240mg, 35% for 160mg, and 33% for control. Safety data were consistent with prior studies.
How this was made
The 30-second read
Why it matters
The miss of the primary endpoint could trigger a sell‑off, but secondary data may offer upside potential.
Market read
First disclosure of pivotal trial data; material for AVBP and oncology biotech peers.
What to watch
Investors may focus on the trend toward overall survival improvement despite primary miss.
Background
ArriVent BioPharma filed an 8‑K reporting its Phase 3 trial results.
Ticker impact
ArriVent BioPharma disclosed Phase 3 FURVENT trial missed its primary PFS endpoint, providing new clinical data.
potential downside as investors price in the miss
First report of pivotal trial data; miss is material for a biotech.
Market effects
May dampen sentiment in the oncology biotech sector.
Limited to US biotech investors.
Low global impact beyond biotech investors.
Counterpoint
Investors could view the secondary endpoint data as a positive signal.
Key entities
- companyArriVent BioPharma, Inc.
Biopharma company developing firmonertinib.